Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew R Smith

Showing results (301-310 of 319) with videos related to

Pageof 32
Sort By:
JCO Precision Oncology|January 31, 2025
Digital Pathology-Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate CancerFelix Y Feng, Matthew R Smith, Fred Saad, et al.
Science (New York, N.Y.)|September 19, 2015
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistanceDavid T Miyamoto, Yu Zheng, Ben S Wittner, et al.
Science Translational Medicine|April 29, 2010
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancerShannon L Stott, Richard J Lee, Sunitha Nagrath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialDavid C Smith, Matthew R Smith, Christopher Sweeney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Advances in treating metastatic bone cancer: summary statement for the First Cambridge ConferenceAllan Lipton, James R Berenson, Jean-Jacques Body, et al.
International Journal of Cancer|August 28, 2007
Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohortsDaphne W Bell, Sang H Kim, Andrew K Godwin, et al.
European Urology|March 18, 2014
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohortEthan Basch, Karen A Autio, Matthew R Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion studyMatthew R Smith, Christopher J Sweeney, Paul G Corn, et al.
European Urology|May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
The New England Journal of Medicine|February 18, 2022
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate CancerMatthew R Smith, Maha Hussain, Fred Saad, et al.
Pageof 32

Showing results (301-310 of 319) with videos related to

Sort By:
Pageof 32
JCO Precision Oncology|January 31, 2025
Digital Pathology-Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate CancerFelix Y Feng, Matthew R Smith, Fred Saad, et al.
Science (New York, N.Y.)|September 19, 2015
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistanceDavid T Miyamoto, Yu Zheng, Ben S Wittner, et al.
Science Translational Medicine|April 29, 2010
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancerShannon L Stott, Richard J Lee, Sunitha Nagrath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialDavid C Smith, Matthew R Smith, Christopher Sweeney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Advances in treating metastatic bone cancer: summary statement for the First Cambridge ConferenceAllan Lipton, James R Berenson, Jean-Jacques Body, et al.
International Journal of Cancer|August 28, 2007
Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohortsDaphne W Bell, Sang H Kim, Andrew K Godwin, et al.
European Urology|March 18, 2014
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohortEthan Basch, Karen A Autio, Matthew R Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion studyMatthew R Smith, Christopher J Sweeney, Paul G Corn, et al.
European Urology|May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
The New England Journal of Medicine|February 18, 2022
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate CancerMatthew R Smith, Maha Hussain, Fred Saad, et al.
Pageof 32